Merged from 2 sources — review for redundancy.
Protein Kinase A (PKA) is a cAMP-dependent serine/threonine kinase that serves as the primary intracellular executor of G-protein coupled receptor signaling. Acting as a molecular switch activated when cAMP levels rise, PKA phosphorylates target proteins across virtually all physiological systems—driving metabolic shifts, gene transcription, synaptic plasticity, and immune modulation. In cPNI, PKA represents the critical junction where psychological states (stress, expectancy, Conditioning) translate into cellular biochemistry.
PKA is like a factory floor manager who stays locked in the break room until receiving specific instructions from upper management. The "upper management" includes stress Hormones like Adrenaline, reward signals like Dopamine, or metabolic controllers like Glucagon—all sending their messages via cAMP couriers. When enough cAMP couriers arrive, they unlock the break room door, releasing the manager (PKA's catalytic subunits) to rush onto the factory floor.
Once released, this manager doesn't do one job—it orchestrates dozens simultaneously. It phosphorylates (stamps approval on) proteins controlling fuel storage ("break down glycogen NOW"), gene expression ("start making more stress response proteins"), neuron communication ("strengthen this synapse for learning"), and immune cell behavior. The same manager can be released in your liver cells (where it triggers glucose release), your brain's reward pathways (where it encodes pleasure and expectancy), or your fat cells (where it initiates Lipolysis). This explains how a single molecule of Adrenaline in your bloodstream during an exam can simultaneously make your heart race, release glucose, sharpen attention, AND reinforce the conditioned association between exam halls and anxiety—all through PKA activation in different tissues.
PKA exists as an inactive tetrameric complex consisting of two regulatory (R) subunits bound to two catalytic (C) subunits (R2C2 configuration). Different PKA isoforms exist based on regulatory subunit type (RI or RII), providing tissue-specific responses and subcellular localization patterns.
Activation cascade:
- G-protein coupled receptor (GPCR) activation → Gsα protein activation → adenylyl cyclase activation → cAMP synthesis
- cAMP binds cooperatively to two sites on each PKA regulatory subunit
- Conformational change in R subunits → dissociation of R2C2 complex
- Free catalytic subunits (now active) phosphorylate serine/threonine residues on target proteins
- Phosphodiesterases (PDEs) degrade cAMP → reassociation of R2C2 → PKA inactivation
Subcellular targeting: A-kinase anchoring proteins (AKAPs) tether PKA to specific cellular locations (membrane, mitochondria, nucleus), ensuring localized responses. Over 50 different AKAPs create spatial specificity—the same cAMP signal produces different outcomes depending on which AKAP-localized PKA pool activates.
Key PKA substrates and pathways:
graph TD
A[PKA Activated] --> B[Metabolic Targets]
A --> C[Transcriptional Targets]
A --> D[Synaptic Targets]
A --> E[Immune Targets]
B --> B1["Hormone-Sensitive Lipase → Lipolysis"]
B --> B2["Phosphorylase Kinase → Glycogenolysis"]
B --> B3["PFK2 inhibition → Glycolysis ↓"]
C --> C1[CREB phosphorylation Ser133]
C1 --> C2[CREB-CBP binding]
C2 --> C3["Gene transcription: BDNF, c-fos, Nr4a1"]
D --> D1["GluR1 phosphorylation → AMPA trafficking"]
D --> D2["RIM1α → Vesicle priming"]
D --> D3["Synapsin I → Neurotransmitter release"]
E --> E1["NF-κB modulation"]
E --> E2["CREB → IL-10 expression"]
E --> E3[Catecholamine receptor sensitivity]
Metabolic effects:
- Phosphorylates and activates hormone-sensitive lipase (HSL) → triglyceride breakdown → free fatty acid release
- Activates phosphorylase kinase → glycogen phosphorylase activation → glucose-1-phosphate release
- Inhibits glycogen synthase → blocks glycogen storage
- Phosphorylates PFK-2/FBPase-2 → fructose-2,6-bisphosphate ↓ → glycolysis inhibition, gluconeogenesis ↑
Transcriptional effects:
- Phosphorylates CREB at Ser133 → recruits CBP/p300 coactivators → transcription of immediate early genes (c-fos, egr-1, Nr4a)
- Upregulates BDNF, neuropeptide Y, enkephalin, tyrosine hydroxylase
- In immune cells: promotes IL-10, reduces TNF-α and IL-12 production
Synaptic plasticity:
- Required for late-phase long-term potentiation (L-LTP) lasting >3 hours
- Phosphorylates GluR1 AMPA receptor subunits → increased surface expression → enhanced synaptic strength
- Phosphorylates synaptic proteins (synapsin I, RIM1α) → increased neurotransmitter release probability
- Nuclear translocation of catalytic subunit → CREB-dependent gene expression → structural synaptic changes
Duration and termination:
- PKA activity peaks within 1-5 minutes of cAMP elevation
- Phosphodiesterase 4 (PDE4) degrades cAMP with t½ ~1-2 minutes
- Protein phosphatases (PP1, PP2A) dephosphorylate PKA substrates
- Regulatory subunits rebind catalytic subunits when cAMP drops below ~10 nM
PKA is the molecular mechanism underlying three critical cPNI phenomena: stress hormone effects, Conditioning responses, and placebo analgesia. Understanding PKA clarifies how psychological states become biochemical realities.
Stress and metabolic dysfunction:
Chronic Adrenaline and Glucagon elevation → sustained PKA activation in adipose tissue → excessive Lipolysis → elevated free fatty acids → insulin resistance and ectopic fat deposition. In chronic stress, PKA-driven metabolic reprogramming favors glucose mobilization and fat oxidation even when nutrients are abundant—a classic mismatch pattern contributing to metabolic syndrome.
Placebo and conditioning mechanisms:
Dopamine D1 receptor activation in nucleus accumbens and Prefrontal cortex → cAMP-PKA pathway → CREB phosphorylation → learning and expectancy encoding. PKA activation in these circuits during placebo administration creates the molecular basis of placebo analgesia—not mere "belief" but measurable opioid release and descending pain inhibition. Studies show PKA inhibitors block placebo responses, confirming this pathway is necessary.
Pharmacological conditioning:
When conditioned stimuli activate Dopamine or noradrenergic pathways, PKA translates this activation into lasting cellular changes through CREB-mediated gene expression. This explains why Pharmacological Conditioning can produce physiological effects (immune suppression, hormone changes) identical to drug administration—the conditioned stimulus triggers the same PKA cascade as the drug itself.
Clinical biomarkers and thresholds:
- cAMP levels in platelets correlate with sympathetic tone (normal: 2-5 pmol/10⁸ platelets)
- PKA activity assays show elevation in PTSD, chronic pain, and treatment-resistant depression
- CREB phosphorylation (pCREB) levels in peripheral blood mononuclear cells reflect chronic stress exposure
Intervention implications:
- Cold exposure and Exercise transiently activate PKA in adipose tissue → adaptive metabolic flexibility
- Chronic psychological stress creates maladaptive PKA activation → therapeutic targets include stress management, Mindfulness, and circadian restoration
- β-blocker therapy reduces PKA activation → potential benefits in anxiety, PTSD, but risks metabolic inflexibility
- Phosphodiesterase inhibitors (increasing cAMP) enhance PKA signaling → used therapeutically in heart failure, but complicate stress physiology
Evolutionary context:
PKA represents an ancient signaling system conserved across eukaryotes, initially coordinating nutrient sensing and stress responses in single-celled organisms. Its co-option for complex learning, reward processing, and immune regulation demonstrates Exaptation—a survival mechanism for acute threats now mediating chronic stress pathology when chronically activated. The mismatch paradigm is evident: PKA perfectly suited for intermittent predator escape, poorly suited for continuous psychosocial stress.
Five metamodels connection:
PKA activation links all five metamodels: it mediates stress responses (Metamodel 0: survival), drives reward learning (Metamodel 1: bonding), coordinates metabolic-immune crosstalk (Metamodel 3), enables context-dependent healing (Metamodel 5: placebo), and can become dysregulated in chronic activation (allostatic load).
- PKA is activated within 30-60 seconds of cAMP elevation; peak activity at 1-5 minutes
- Requires cooperative binding of 4 cAMP molecules (2 per regulatory subunit) for full activation
- Catalytic subunits have Km for ATP ~15 μM; activity increases 50-100 fold upon activation
- Over 100 confirmed PKA substrates across metabolism, transcription, cytoskeleton, and ion channels
- CREB phosphorylation at Ser133 is the canonical transcriptional readout; occurs within 5-15 minutes
- Late-phase LTP (>3 hours) absolutely requires PKA activity; early-phase LTP (<1 hour) does not
- PKA inhibitor H89 blocks placebo analgesia in rodent and human studies at 10-30 μM
- Type I PKA (RIα/β) is cytoplasmic; Type II PKA (RIIα/β) is AKAP-anchored and spatially restricted
- Phosphodiesterase 4 (PDE4) terminates PKA signals; genetic PDE4 variants associate with depression and schizophrenia risk
- PKA activity in adipocytes increases 5-10 fold during fasting or acute stress; sustained elevation drives insulin resistance
- D1 Dopamine receptor density in reward pathways determines magnitude of PKA-mediated placebo responses
- Cortisol potentiates PKA effects on metabolism via transcriptional upregulation of PKA substrates
- cAMP — second messenger that directly binds and activates PKA regulatory subunits; each PKA tetramer requires 4 cAMP molecules
- CREB — primary transcription factor phosphorylated by PKA at Ser133; mediates long-term gene expression changes underlying learning and metabolism
- Dopamine — D1 receptor activation → Gsα → cAMP → PKA pathway; critical for reward learning and placebo analgesia
- Adrenaline — β-adrenergic receptor activation → Gsα → cAMP → PKA cascade; drives acute stress metabolism and Lipolysis
- Glucagon — activates PKA in hepatocytes → glycogenolysis and gluconeogenesis; counter-regulatory to insulin
- Placebo analgesia — PKA activation in nucleus accumbens and prefrontal cortex encodes expectancy and triggers opioid release
- Pharmacological Conditioning — conditioned stimuli activate PKA via Dopamine pathways; molecular basis of conditioned drug responses
- Nucleus Accumbens (NAc) — high D1 receptor density; PKA signaling here mediates reward, motivation, and conditioned responses
- Prefrontal cortex — PKA-CREB pathway underlies working memory and executive function; dysregulated in chronic stress
- beta-adrenergic receptors — Gs-coupled receptors; Adrenaline/Noradrenaline binding → cAMP-PKA activation → metabolic and cardiac effects
- PKC — parallel kinase pathway activated by Gq-coupled receptors; often works synergistically with PKA in immune cells
- hormone-sensitive lipase — rate-limiting enzyme for Lipolysis; PKA phosphorylation at Ser563, Ser659, Ser660 increases activity 50-fold
- BDNF — CREB-dependent gene; PKA activation increases BDNF transcription → neuroplasticity and memory consolidation
- long-term potentiation — late-phase LTP requires PKA → CREB → protein synthesis; early-phase LTP is PKA-independent
- chronic stress — sustained PKA activation in metabolic tissues → insulin resistance, visceral adiposity, inflammation
- reward pathways — mesolimbic Dopamine → D1 → PKA → reinforcement learning; basis for addiction and Conditioning
- Conditioning — PKA translates associative learning into molecular changes; necessary for acquisition and consolidation
- NF-κB — PKA can both activate (via IKK phosphorylation) and inhibit (via CREB → IL-10) depending on cell type and context
- IL-10 — anti-inflammatory cytokine upregulated by PKA-CREB pathway in immune cells; mediates catecholamine immunosuppression
- Cortisol — glucocorticoids sensitize cells to PKA effects by upregulating PKA substrates and AKAPs; synergistic metabolic reprogramming
- mTORC1 — PKA can activate mTORC1 via TSC2 phosphorylation; coordinates growth and metabolism with nutrient/stress signals
- neuroplasticity — PKA-dependent synaptic strengthening and CREB-mediated structural changes; impaired in chronic stress and depression
- Lipolysis — PKA phosphorylates HSL, perilipin, and ATGL → triglyceride breakdown; excessive activation in chronic stress → free fatty acid toxicity
- insulin resistance — chronic PKA-driven Lipolysis → elevated free fatty acids → lipotoxicity → impaired insulin signaling
- context processing — PKA activation in hippocampus and amygdala encodes contextual associations; basis for conditioned immune and hormonal responses
Protein Kinase A (PKA) is a cAMP-dependent serine/threonine kinase that acts as the primary intracellular effector of cyclic AMP signaling, mediating responses to Hormones, Neurotransmitters, and immune signals by phosphorylating target proteins. PKA sits at a critical hub connecting the neuro-endocrino-immune interface, translating extracellular information (from dopamine, adrenaline, glucagon, and cytokines) into intracellular actions that regulate metabolism, gene transcription, neuroplasticity, pain processing, and immune function. Its role in placebo analgesia and central sensitization makes it essential to understanding context-dependent healing and chronic pain in cPNI.
Think of PKA as a security lock on a factory door that only opens when the right combination is entered. The combination is cAMP—when four cAMP molecules bind to the lock (the regulatory subunits), the lock falls apart and releases the workers (catalytic subunits) into the factory floor. These workers are specialist installers who carry phosphate stamps—they rush around stamping "ACTIVATE" or "DEACTIVATE" on machines (proteins) by adding phosphate groups to specific spots (serine and threonine residues).
What makes this system brilliant is its dual function depending on which factory floor you're on. In the liver factory, PKA workers stamp "BREAK DOWN" on glycogen storage tanks (activating glycogenolysis) and "STOP MAKING" on glycogen synthesis machines—mobilizing energy. In the pain processing plant, those same workers stamp "MORE SENSITIVE" on pain receptors like TRPV1 and NMDA receptor—turning up the pain volume. But in the reward pathways of the brain, when Dopamine triggers cAMP production, PKA stamps "FEEL GOOD" on CREB transcription factors, which then write new instruction manuals (genes) for learning, memory, and—crucially—placebo analgesia.
The factory stays quiet when cAMP levels drop (phosphodiesterases vacuum up the cAMP molecules), and the workers get locked back up in their security complex. This on-off switch operates at timescales of seconds to minutes, making PKA a rapid responder to changing physiological demands.
PKA exists as an inactive tetrameric complex composed of two regulatory (R) subunits and two catalytic (C) subunits (R₂C₂ structure). The mechanism unfolds as follows:
Activation cascade:
- Extracellular signal (hormone/neurotransmitter) binds to Gs-coupled G-Protein Receptor (e.g., beta-2 adrenergic receptor, dopamine D1 receptor, glucagon receptor)
- Gs protein activates adenylyl cyclase on the inner membrane
- Adenylyl cyclase converts ATP → cAMP
- Four cAMP molecules bind cooperatively to the two regulatory subunits (two per R subunit)
- cAMP binding causes conformational change in R subunits, releasing them from C subunits
- Free catalytic subunits are now enzymatically active
Phosphorylation targets (substrate specificity):
- PKA recognizes the consensus sequence: Arg-Arg-X-Ser/Thr (where X is any amino acid)
- Phosphorylates serine/threonine residues by transferring γ-phosphate from ATP to hydroxyl groups
- Each catalytic subunit can phosphorylate multiple targets simultaneously
Key substrate pathways:
Metabolic targets:
Transcriptional targets:
- CREB (cAMP Response Element Binding protein) phosphorylated at Ser133
- Phospho-CREB binds CRE sequences in gene promoters
- Recruits CBP/p300 coactivators → transcription of genes for BDNF, c-Fos, dynorphin, neuroplasticity markers
Pain sensitization targets:
- TRPV1 phosphorylation at Ser502, Ser800 → channel sensitization, reduced activation threshold (from ~43°C to ~35°C)
- NMDA receptor NR1 subunit phosphorylation at Ser897 → enhanced calcium influx, increased excitability
- GluR1 AMPA receptor phosphorylation → increased surface expression and synaptic strength
- Nav1.7 sodium channel phosphorylation → enhanced excitability in nociceptors
Termination mechanisms:
- Phosphodiesterases (PDEs) hydrolyze cAMP → 5'-AMP (especially PDE4 in immune and brain cells)
- Protein phosphatases (PP1, PP2A, PP2B) dephosphorylate PKA substrates
- PKI (PKA inhibitor protein) binds and inactivates free catalytic subunits
- Regulatory subunits re-associate with catalytic subunits when cAMP drops
graph TD
A[Hormone/Neurotransmitter] --> B[Gs-coupled GPCR]
B --> C[Adenylyl Cyclase]
C --> D["ATP → cAMP"]
D --> E[cAMP binds R2C2 complex]
E --> F[Catalytic subunits released]
F --> G1[Metabolic targets]
F --> G2[Transcription factors]
F --> G3[Ion channels]
F --> G4[Synaptic proteins]
G1 --> H1["Glycogen breakdown↑"]
G1 --> H2["Lipolysis↑"]
G1 --> H3["Gluconeogenesis↑"]
G2 --> I1[CREB-Ser133-P]
I1 --> I2[Gene transcription]
I2 --> I3[BDNF, c-Fos, memory proteins]
G3 --> J1[TRPV1 sensitization]
G3 --> J2[NMDA-R potentiation]
G3 --> J3[Sodium channel activation]
G4 --> K1["Neurotransmitter release↑"]
G4 --> K2[Long-term potentiation]
D --> L[Phosphodiesterases]
L --> M[cAMP degradation]
M --> N[PKA inactivation]
PKA isoforms:
- Type I PKA (RIα, RIβ regulatory subunits): predominantly cytoplasmic, involved in metabolism
- Type II PKA (RIIα, RIIβ regulatory subunits): membrane-associated via AKAPs (A-Kinase Anchoring Proteins), involved in localized signaling (synapses, pain pathways, immune synapses)
A-Kinase Anchoring Proteins (AKAPs) scaffold PKA to specific subcellular locations:
- AKAP79/150 at postsynaptic sites → links PKA to NMDA receptor and AMPA receptors
- AKAP18 in heart → links PKA to calcium channels
- This spatial organization ensures signal specificity despite ubiquitous cAMP
Role in pain and central sensitization:
PKA is a critical driver of chronic pain through central sensitization mechanisms. In fibromyalgia, chronic lower back pain, and neuropathic pain, sustained PKA activation in the dorsal horn phosphorylates TRPV1 and NMDA receptor, creating a state of hyperexcitability where normal touch becomes painful (allodynia) and painful stimuli are amplified (hyperalgesia). This explains why PKA inhibitors (H-89, KT5720 in research; clinical development ongoing) reduce pain sensitivity in animal models. In cPNI practice, interventions that reduce sympathetic tone (cold exposure, breathwork, sleep optimization) lower adrenaline→cAMP→PKA signaling in pain circuits.
Placebo analgesia and expectation:
PKA is the molecular bridge between belief and biology in placebo analgesia. When a patient expects pain relief (conditioned by verbal suggestion, ritual, or past experience), this activates dopamine release from the ventral tegmental area into the Nucleus Accumbens (NAc) and prefrontal cortex. Dopamine binds D1 receptors (Gs-coupled) → cAMP↑ → PKA↑ → CREB phosphorylation → transcription of endogenous opioid genes (preproenkephalin). PKA also directly modulates opioid receptor sensitivity. This pathway explains why expectation-enhanced placebo can produce 30-50% pain reduction in clinical trials. Clinically: treatment rituals, open vs. hidden administration, and therapeutic alliance all modulate this dopamine-PKA axis. Exam-relevant: Blocking PKA with H-89 abolishes placebo analgesia in rodent models (Amir et al., 2010).
Metabolic regulation:
PKA is the primary effector of catabolic hormones (adrenaline, glucagon, ACTH). In insulin resistance, chronic PKA activation in adipocytes (from elevated adrenaline in chronic stress) drives excessive lipolysis → elevated free fatty acids → ectopic fat deposition and lipotoxicity. PKA also regulates hepatic glucose output—relevant in Type 2 Diabetes where nocturnal glucagon-PKA signaling drives fasting hyperglycemia. Interventions: intermittent fasting creates periods of low cAMP (low glucagon), allowing PKA to "rest"; beta-blocker medications reduce beta-2 adrenergic receptor-PKA signaling.
Immune function:
In immune cells, PKA has context-dependent roles. Adrenaline→beta-2 adrenergic receptor→cAMP→PKA signaling in macrophages suppresses NF-kB activation, reducing pro-inflammatory cytokine production (IL-1β, TNF-α). This is part of the cholinergic anti-inflammatory pathway extension via sympathetic nerves. However, in T cells, PKA activation can enhance Th2 differentiation over Th1, shifting immune balance. Clinical implication: chronic sympathetic activation (chronic stress, poor sleep) creates immune dysregulation through sustained PKA activity—relevant in autoimmune diseases, allergies, and infection susceptibility.
Learning, memory, and neuroplasticity:
PKA-mediated CREB phosphorylation is required for consolidation of long-term memory (both declarative and conditioned responses). In long-term potentiation (the cellular basis of learning), PKA phosphorylates GluR1 AMPA receptors, increasing their synaptic insertion—strengthening synapses. This is why PKA is central to response conditioning in placebo/nocebo effects and why repeated treatment contexts (conditioned stimuli) produce progressively stronger therapeutic responses. Clinically: creating consistent treatment rituals leverages PKA-dependent associative learning.
Metamodel connections:
- Metamodel 0 (Evolution): PKA is an ancient kinase (present in yeast); its role in stress responses and memory reflects evolutionarily conserved survival mechanisms
- Metamodel 1 (Inflammation): PKA regulates immune cell function and pro-/anti-inflammatory balance
- Metamodel 3 (Stress axes): PKA is the primary intracellular effector of stress hormones (cortisol via non-genomic pathways, adrenaline, CRH)
- Metamodel 5 (Context/Placebo): PKA mediates the neurobiological substrate of expectation, conditioning, and context-dependent healing
Intervention strategies:
- Reduce chronic PKA activation: stress management, sleep optimization (reduces nocturnal adrenaline), Cold exposure (reduces sympathetic tone), meditation (reduces cortisol and catecholamines)
- Leverage PKA in placebo: enhance treatment rituals, open-label administration with explanation of expectation mechanisms, consistent therapeutic alliance
- Nutritional modulation: Curcumin inhibits PKA in some contexts; Omega-3 (DHA) modulates cAMP-PKA signaling in neurons
- Pharmacological (research): PKA inhibitors under investigation for chronic pain (not yet clinical standard)
Clinical thresholds:
- Pain threshold reduction: PKA activation in nociceptors can lower thermal pain threshold from ~43°C to ~35°C (relevant in inflammatory pain)
- Placebo magnitude: Dopamine-PKA pathway activation correlates with 20-60% pain reduction in responders vs. non-responders
- Metabolic effects: Chronic PKA activation (from sustained catecholamine elevation) visible as elevated plasma free fatty acids >0.6 mmol/L and nocturnal glucose >5.6 mmol/L
- PKA is a tetrameric enzyme (R₂C₂) that dissociates when four cAMP molecules bind to regulatory subunits
- Phosphorylates serine/threonine residues on target proteins using ATP as phosphate donor
- Recognizes consensus sequence Arg-Arg-X-Ser/Thr for substrate specificity
- Two isoforms: Type I (cytoplasmic, metabolic) and Type II (membrane-anchored via AKAPs, synaptic/immune)
- CREB phosphorylation at Ser133 is required for long-term memory consolidation and placebo analgesia
- TRPV1 phosphorylation reduces heat activation threshold from ~43°C to ~35°C, driving thermal hyperalgesia
- NMDA receptor phosphorylation at NR1-Ser897 increases calcium influx and synaptic strength in pain pathways
- Activated by catabolic hormones: adrenaline, glucagon, ACTH, dopamine (D1 receptors)
- Terminated by phosphodiesterases (especially PDE4) degrading cAMP and protein phosphatases removing phosphates
- H-89 (experimental PKA inhibitor) abolishes placebo analgesia in animal models—demonstrating necessity of PKA for expectation-induced pain relief
- PKA activity duration: seconds to minutes for acute signaling; hours to days for gene transcription effects via CREB
- In chronic pain sensitization, sustained PKA activation creates maladaptive plasticity—potential therapeutic target
- Cross-system integration: PKA connects sympathetic nervous system (adrenaline), reward system (dopamine), metabolic regulation (glucagon), and immune function (beta-adrenergic signaling in leukocytes)
- cAMP — second messenger that activates PKA by binding regulatory subunits, causing dissociation and release of catalytic subunits
- dopamine — stimulates cAMP and PKA in reward pathways via D1 receptors; central to placebo analgesia and expectation effects
- placebo analgesia — mediated by expectation-induced dopamine release → cAMP-PKA → CREB phosphorylation → endogenous opioid transcription
- TRPV1 — PKA phosphorylation at Ser502/Ser800 sensitizes this capsaicin/heat receptor, lowering activation threshold and driving inflammatory pain
- NMDA receptor — PKA phosphorylation of NR1 subunit at Ser897 enhances calcium influx, critical for central sensitization and long-term potentiation
- chronic pain — involves excessive PKA-mediated sensitization of pain pathways through phosphorylation of TRPV1, NMDA receptors, and sodium channels
- central sensitization — PKA contributes to enhanced pain processing by phosphorylating dorsal horn receptors and synaptic proteins
- Nucleus Accumbens (NAc) — PKA activity here mediates reward learning and placebo responses via dopamine-cAMP-CREB pathway
- CREB — transcription factor phosphorylated by PKA at Ser133; regulates genes for BDNF, memory proteins, and endogenous opioids
- glucagon — hormone that increases cAMP via Gs-coupled receptor, activating PKA to mobilize hepatic glucose and lipid stores
- adrenaline — activates PKA via beta-adrenergic receptors, driving lipolysis, glycogenolysis, and modulating immune cell function
- beta-2 adrenergic receptor — Gs-coupled receptor that activates adenylyl cyclase → cAMP → PKA in response to catecholamines
- glycogen metabolism — PKA activates glycogen breakdown (via phosphorylase kinase) and inhibits synthesis (via glycogen synthase phosphorylation)
- lipolysis — PKA activates hormone-sensitive lipase (HSL), releasing free fatty acids from adipocytes during fasting or stress
- long-term potentiation — PKA required for synaptic strengthening through AMPA receptor phosphorylation and gene transcription via CREB
- Conditioning — PKA mediates associative learning by linking stimulus-response pairing to synaptic plasticity and CREB-dependent memory consolidation
- PKC — parallel kinase pathway activated by calcium and DAG; converges with PKA on pain receptors and learning mechanisms
- phosphorylation — PKA's primary enzymatic function; adds phosphate groups to serine/threonine residues, altering protein activity
- cholinergic anti-inflammatory pathway — PKA mediates sympathetic arm of this reflex (adrenaline→beta-receptor→PKA→NF-κB suppression in immune cells)
- insulin resistance — chronic PKA activation from stress hormones drives excessive lipolysis and free fatty acid release, worsening metabolic dysfunction
- nocebo effect — negative expectations reduce dopamine release, limiting PKA-CREB-mediated endogenous analgesia; can worsen pain sensitivity
- BDNF — brain-derived neurotrophic factor transcription induced by PKA-phosphorylated CREB; critical for neuroplasticity and antidepressant effects
- treatment context — consistent treatment rituals activate dopamine-PKA pathways via conditioning, enhancing therapeutic outcomes
- response conditioning — PKA-dependent mechanism where repeated pairing of context+drug creates conditioned physiological responses
- chronic stress — elevates catecholamines, driving sustained PKA activation in immune, metabolic, and neural tissues—contributing to allostatic load